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Abstract 
 
The introduction of massive parallel sequencing has led to the identification of multiple novel genes for 
intellectual disability (ID) as well as epilepsy. Whereas dominant de novo mutations have been proven to be a 
leading cause for these disorders, they do not apply to families suggestive of an autosomal recessive 
inheritance pattern. In this study, we combined the use of linkage analysis with exome sequencing to elucidate 
the cause of moderate non-syndromic ID, epilepsy and behavioural problems in a consanguineous Iraqi family. 
A founder missense mutation was identified in STYXL1. We propose this as a novel candidate gene involved in 
ID, accompanied by seizures and behavioural problems. Our findings further confirm the genetic heterogeneity 
of cognitive disorders and genetic epilepsy. 
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Introduction 
 
The introduction of massive parallel sequencing has led to the identification of multiple novel genes 
for intellectual disability (ID) as well as epilepsy (Barcia et al., 2012, de Ligt et al., 2012, Heron et al., 2012a, 
Heron et al., 2012b, Rauch et al., 2012). A significant amount of research has focused on the occurrence of 
dominant de novo mutations, revealed by trio sequencing. Indeed, dominant de novo mutations have been 
proven to be a leading cause of ID in the Western world (de Ligt et al., 2012, Rauch et al., 2012). However, this 
approach is not feasible for families with multiple affected individuals in the same generation, which often 
suggests an autosomal recessive inheritance pattern.  
Consanguineous couples with multiple affected children form a distinct group, since linkage analysis in 
these families often allows to delineate restricted region(s) containing the causal genetic defect. Genetic 
investigations can therefore focus on a specific region, filtering out many irrelevant variants in the case of 
whole genome or exome sequencing. An alternative approach is the customized targeting and deep sequencing 
of the linkage interval only (Najmabadi et al., 2011). 
In this study, we combined the use of linkage analysis with exome sequencing to elucidate the cause of 
moderate non-syndromic ID, epilepsy and behavioural problems in a consanguineous Iraqi family. A founder 
mutation was identified in a novel candidate gene, further confirming the genetic heterogeneity of cognitive 
disorders.  
 
Clinical description 
 
 The pedigree of the family is depicted in Figure 1a. The proband (Fig. 1a, V.1) was referred to the 
department of Paediatric Neurology at the age of 15 years due to behavioural problems and developmental 
delay accompanied by seizures. Focal epilepsy started at the age of 3 years. Seizures were characterized by 
vocalisation, upward gaze, clonic movements of the right arm, followed by generalisation. EEGs showed spikes 
over occipital and frontal derivations and background slowing. MRI of the brain was normal. He was treated 
with carbamazepine, oxcarbazepine, topiramate, and became seizure free on lamotrigine 250 mg BID and 
valproate 1 g BID. He followed special education and at the age of 24 still needed supervision during his general 
daily activities. Karyotype and FMR1 gene analysis were normal.  
 Brother V.3 (Fig. 1a) was diagnosed with autism and mild ID and he was admitted to the psychiatric 
ward at the age of 16 due to psychosis and aggressive behaviour. He was also treated for mild epilepsy since 
the age of 3 years. He had a few generalized tonic-clonic seizures. EEG showed mild to moderate slow 
background without epileptic discharges. MRI of the brain was normal. He remained seizure free on valproate 
500 mg BID. 
 Individual V.6 (Fig. 1a) was the youngest affected sibling. He had a delayed speech development, mild 
ID and epilepsy. The epilepsy started at the age of 5 years. He had focal and generalized tonic-clonic seizures. 
MRI of the brain was normal. EEG showed frequent multifocal independent spike discharges (MISD) and slow 
background (Fig. 2). Seizures were controlled on valproate 250 mg TID. He was also diagnosed with an autism 
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spectrum disorder (ASD) and showed problematic behaviour including anxiety and sleep disturbance. Array-
CGH was normal.  
 All three affected siblings were non-dysmorphic. Screening for inborn errors of metabolism showed 
normal results. Parents were consanguineous and from Asian origin. They also had three unaffected children 
(V.2, V.4 and V.5, Fig. 1a) and additional family history was negative.  
 
Methods  
 
Linkage analysis and haplotyping 
 
Genome-wide parametric linkage analysis, as well as haplotyping was performed with Merlin software 
(Abecasis et al., 2002). A dense SNP marker set derived from the Affymetrix SNP array 6.0 platform was used in 
a recessive model. As a requirement of Merlin analysis sex-averaged SNP genetic distances derived from 
deCODE (Kong et al., 2002) were used. Genotyping was done on DNA extracted from peripheral white blood 
cells, obtained from the parents, their three unaffected and three affected children. Copy number analysis and 
SNP B-allele frequency computation was carried out by PennCNV and visualised using Circos. (Wang et al., 
2007, Krzywinski et al., 2009).  
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Fig. 1. Pedigree, copy number profiling and linkage-based analysis. a. Genome-wide SNP B-allele fraction and relative copy-
number (logR) profiles of the siblings. The pedigree of the family is depicted in the middle of the Circos-plot. b. A zoomed in 
illustration of chromosome 7 specific SNP B-allele fraction and relative copy-number (logR) profiles. The physical position of 
STYXL1 is indicated by an orange arrow and dashed line. c. Linkage-based analysis of Chromosome 7. 
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Fig. 2. EEG of individual V.6. The interictal EEG showed frequent multifocal independent spike discharges (MISD): A. right 
frontal (F4), B. left centroparietal (C3, P3), C. right central (C4) and left frontal (F3). Longitudinal bipolar montage. Time 
base: 30 mm/s; sensitivity: 150 μV/cm; high cut: 15.0 Hz; low cut: 0.53 Hz. 
 
Exome sequencing 
 
DNA samples of the parents, one affected (V.1) and one unaffected (V.5) sibling were fragmented by sonication 
and libraries were prepared with the TruSeq DNA library kit (Illumina) as per the manufacturer’s protocol. 
Exome capturing was performed using the in-solution NimbleGen SeqCap EZ Human Exome Library v2. Exome 
sequencing was performed on the Illumina HiSeq2000 platform. Paired-end sequencing (2X75 bp) led to an 
average of 5-6 Gb of data per exome. The mean coverage was 96x (Table 1). 
 
Base-calling, alignment and variant calling were performed using the GATK package (McKenna et al., 2010). For 
annotation purposes, Annovar, as well as an in-house designed software Annotate-it were used (Wang et al., 
2010, Sifrim et al., 2012). Data analysis was based on a recessive inheritance pattern. Although homozygous 
mutations seemed more likely based on the consanguinity factor, compound heterozygous variants were also 
taken into account. Data from linkage analysis were used as an additional filtering tool. All filtering steps 
included exonic nonsynonymous and splice-site variants only and presence in the 1000 Genomes Project with a 
maximum minor allele frequency (MAF) of 3% (last accessed on 21/08/2014). 
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Sanger sequencing and X-inactivation studies 
 
Sanger sequencing was applied to confirm the presence of single-nucleotide variants found by exome 
sequencing, as described previously (Isrie et al., 2013). X-inactivation studies were also performed as described 
previously (Froyen et al., 2007). 
 
Expression analysis 
 
Samples from the proband (V.1), his father (IV.1) and four random control samples were analysed for 
expression levels of STYXL1 mRNA. Total RNA was extracted from EBV transformed lymphoblastoid cells using 
the RNeasy Mini Kit (Qiagen). cDNA synthesis was performed by taking 1µg of RNA using Superscript III First-
Strand Synthesis SuperMix for qRT-PCR (Invitrogen). Quantitative RT-PCR was performed using gene specific 
primers and the SYBR Green PCR Master Mix (Life Technologies) (see supplementary Table S1 for primer 
sequences). Relative gene expression was calculated in Microsoft Excel using the 2(−ΔΔCt) method comparing 
samples and expression levels to four control samples and housekeeping genes GAPDH and GUSB. The 
unpaired t-test was applied for statistical purposes.   
 
Table 1 
Quality metrics of exome sequencing data (obtained from Picard metrics). 
 
Results 
 
Considering pedigree-derived information, linkage analysis and X-inactivation studies were performed. 
Subsequently, exome sequencing was used to seek the pathogenic mutation in this family. An overview of 
quality metrics of the exome sequencing is depicted in Table 1. Filtering was based on the presence of 
homozygous and compound heterozygous variants, respectively. In addition, a filtering approach for X-linked 
variants was applied, which however did not lead to any candidate variants. Eventually, qRT-PCR was 
performed to investigate expression levels of the most promising candidate gene. 
 
  
Individual Father Mother Affected Unaffected 
Total reads 
(number) 
127,435,484 101,786,244 122,610,966 109,049,332 
Aligned reads 
passed filtering (%) 
93.9 93.9 93.9 94.0 
Mean target 
coverage (x) 
110 80 100 96 
Target bases with 
≥20x coverage (%) 
85.2 80.8 84.0 83.1 
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Linkage analysis and X-inactivation studies  
 
Parametric linkage analysis for a recessive disorder revealed a 4.5 Mb region on chromosome 7 and an 11.8 Mb 
region on chromosome 17, respectively. The maximum LOD-score obtained was 1.579. Furthermore, affected 
siblings were sharing the same haplotype block. 
X-inactivation studies in the mother showed a random pattern (67/33).  
 
Filtering for homozygous variants 
 
Exome sequencing resulted in a total number of 36,091 variants. Table 2 illustrates the filtering strategy used, 
resulting in a total of eleven potentially interesting homozygous variants; of which three mapped to the 
respective linkage regions (see Table S2 for more details). Seven variants outside the linkage regions were 
validated with Sanger, however, did not segregate with the disease in the family. One other variant 
(SPATA31C1) was discarded because of homozygous presence in normal individuals (NHLBI Exome Variant 
Server - accessed 21/08/2014). The three remaining variants were missense variants in STYXL1 (p.P311A) and 
LRRC37A2 (p.E1224G) and a splice-site variant in MDH2 (p.K185=). Since the LRRC37A2 variant could not be 
validated, segregation studies of the two remaining variants were performed, confirming segregation with 
disease for both of them. The STYXL1 variant was predicted to be probably damaging by PolyPhen-2, SIFT as 
well as MutationTaster2 (Ng and Henikoff, 2003, Adzhubei et al., 2010, Schwarz et al., 2014). The MDH2 variant 
was predicted to be tolerated by SIFT, but damaging by MutationTaster. Since this concerned a synonymous 
variant, prediction through PolyPhen-2 was unavailable. 
 
A second filtering approach focused on all homozygous variants in the linkage regions. This resulted in 584 
variants. Out of these, the rare (i.e. with 1000G MAF ≤ 3%) and exonic nonsynonymous or splice-site variants 
were retained, resulting in the same three variants as described before and thus confirming results from the 
previous filtering strategy.   
 
Filtering for compound heterozygous variants 
 
The autosomal recessive hypothesis also prompted a search for compound heterozygous mutations. A similar 
filtering strategy as described in Table 2 was applied to the exome sequencing data, leading to five rare 
compound heterozygous variants in the proband, not shared with his unaffected sibling V.5 (see Table S2). The 
only and most interesting candidates were two missense variants in ANK3 (p.P1489S and p.S2044G), a gene 
recently implicated in moderate ID, hypotonia, spasticity and behavioural problems in another consanguineous 
family (Iqbal et al., 2013). However, further segregation analysis indicated the presence of these compound 
heterozygous variants in an unaffected sibling.  
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Table 2 
Filtering strategy for homozygous variants.  
 
 
 
 
 
 
 
 
 
 
 
Functional investigation of candidate genes 
 
To our knowledge, both candidate genes, MDH2 and STYXL1, have not been implicated in a developmental 
phenotype before.  
 
MDH2 (OMIM *154100) encodes a malate dehydrogenase that is bound to mitochondria in both placenta and 
leucocytes. Since less is known about the function of the protein and it was expected to have metabolic effects, 
a specific metabolic testing was performed comprising levels of organic acids (urine) and lactate (blood and 
urine). Both these parameters were normal in the proband and his two affected siblings. Therefore, the variant 
in MDH2 was not believed to have any pathogenic effects explaining the phenotype.  
 
For the second candidate gene STYXL1, qRT-PCR was chosen to investigate expression levels in mRNA. 
Expression analysis using two probes in STYXL1 in the proband V.1 versus control samples showed a significant 
reduction of expression in proband V.1 (p < 0.0001) (Fig. 3). Comparison of expression levels between controls 
and the carrier father didn’t show significant differences (p=0.29 for probe 1 and p=0.81 for probe 2).  
 
Discussion 
 
 In this study, we describe for the first time a homozygous missense mutation (p.P311A) in STYXL1, 
segregating with ID, seizures, and a behavioural phenotype in three siblings from a consanguineous family. The 
mutation was discovered by exome sequencing and linkage studies and further confirmed with segregation 
analysis. On mRNA level, a significant reduction in transcript levels of STYXL1 was discovered in the proband 
carrying a homozygous mutation and not in his carrier father.  
Filtering criteria Number of variants 
total 36,091 
exonic and nonsynonymous, splice-site variants or 
indels causing frameshift 
19,287 
homozygous in affected proband V.1 3,151 
heterozygous in parents (IV.1 and IV.2) and not 
homozygous in unaffected sibling V.5 
325 
1000G ≤ 0.03 11 
in linkage regions  3 
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Fig. 3. Expression levels of STYXL1 mRNA in the proband and father versus controls.  
 
STYXL1 (also known as DUSP24; MK-STYX) is officially termed serine/threonine/tyrosine interacting-like 1 gene 
and encodes a largely uncharacterized pseudophosphatase. It belongs to the superfamily of protein tyrosine 
phosphatases (PTPs), which form critical components of multiple signalling networks and are important 
regulators of many fundamental physiological processes. The subgroup of mitogen-activated protein kinase 
phosphatases (MKPs) are specifically known to dephosphorylate mitogen-activated protein kinases (MAPKs) 
(Patterson et al., 2009). Although part of this subgroup, STYXL1 lacks phosphatase activity due to presence of a 
serine residue instead of a conserved cysteine residue in the catalytic loop. Nevertheless, owing to the fact that 
STYX domains are evolutionarily conserved, they are expected to perform distinct non-phosphatase functions 
(Wishart and Dixon, 1998). One such function could for example be related to the substrate-binding activity of 
the STYXL1 protein that is still intact (Niemi et al., 2014). 
 Niemi and colleagues recently demonstrated that small interfering RNA (siRNA)-mediated knockdown 
of STYXL1 induces chemoresistance, while overexpression of the protein induces cell death (Niemi et al., 2011). 
They also showed that cell proliferation and MAPK signalling are not affected by the knockdown. Two 
interaction partners of STYXL1 have been described so far; PTPMT1 and G3BP1 (Hinton et al., 2010, Niemi et 
al., 2014). Barr and colleagues further confirmed the role of STYXL1 as a regulator in the stress response 
pathway (Barr et al., 2013). It can be concluded that, although a significant amount of fundamental research on 
STYXL1 has been conducted; little to no information is available about its role in developmental processes.  
 STYXL1 localizes to mitochondria (Niemi et al., 2011) and is expressed in multiple mammalian tissues. 
In brain, expression is high in the hippocampus, hypothalamus and the olfactory bulb (Hawrylycz et al., 2012). 
The gene and the mutated amino acid both are conserved among different species (Pollard et al., 2010). The 
deleterious effect of the p.P311A mutation was predicted by different algorithms (Ng and Henikoff, 2003, 
Adzhubei et al., 2010, Schwarz et al., 2014). In addition, the low frequency of heterozygous carriers, also argues 
for its deleterious effect (Kryukov et al., 2007). However, since the mutation is located at the end of the protein 
and outside a specific protein domain, it was surprising to find diminished mRNA expression levels in the 
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proband. We have no readily explanation for this observation.It has been shown that codon usage influences 
gene expression, although the mechanisms are still unclear (Novoa and Ribas de Pouplana, 2012). Therefore, it 
can be hypothesized that the triplet codon GCG for alanine has negatively influenced STYXL1 expression, 
especially since this is the least used codon for this amino acid (Guigo, 1999). Another potential explanation is 
the fact that missense exonic mutations can also affect splicing, as was shown in a recent paper (Xiong, 2015). 
 In the present family, all affected brothers shared features of ID, epilepsy and behavioural problems. 
The ID and epilepsy with the interictal EEG pattern of MISD suggests that the mutation causes a widespread 
cerebral cortical dysfunctioning. The severity level of the disorder was, however, different among the affected 
siblings, suggesting the influence of environmental or other genetic factors on the clinical outcome.   
 Taken together, our findings revealed STYXL1 as a novel candidate gene for moderate ID, seizures and 
behavioural complexities. Identification of additional patients with a mutation in STYXL1 together with a 
comparable phenotype would further support pathogenicity. In addition, future challenges include determining 
the role of STYXL1 in neurodevelopmental processes and building insights into the molecular mechanisms 
underlying the pathophysiology of STYXL1 mutations.  
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http://circos.ca/ 
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Exome Variant Server, NHLBI GO Exome sequencing project (ESP), Seattle, WA 
http://evs.gs.washington.edu/EVS/ [June 2014] 
 
MutationTaster 
http://mutationtaster.org/ 
 
Picard metrics 
http://picard.sourceforge.net/index.shtml/ 
 
PolyPhen-2 
http://genetics.bwh.harvard.edu/pph2/ 
 
R (data visualization) 
http://cran.r-project.org 
 
SUPPLEMENTARY DATA  
Table S1 
Primers used for quantitative RT-PCR 
 
STYXL1_ex3_FWD GTGATCACTGCCCTTCGAGT  
STYXL1_ex4_REV CACACACTCCAGGTCCACAG 75 bp 
STYXL1_ex8_FWD CCGCCATCATAGCCTACCT  
STYXL1_ex9_REV CAATCCCCGATTTGGACA 104 bp 
 
Table S2 
Exome sequencing post-filtering variants, homozygous or compound heterozygous in proband V.1. (MAF=minor allele 
frequency; n/a = not applicable)   
 
To Professor Dr. A. Verloes      Leuven, 14-01-2015 
Editor 
European Journal of Medical Genetics 
Dept. of Medical Genetics, Clinical Genetic Unit 
CHU Robert Debré 
48 Boulevard Sérurier 
75935 Paris 
France 
 
 
 
Dear Professor Verloes, 
 
 
Thank you very much for the review of our Exome Report entitled “Homozygous 
missense mutation in STYXL1 associated with moderate intellectual disability, epilepsy and 
behavioural complexities”, manuscript n° EJMG-D-14-00412.  
We appreciate the time and useful comments of both reviewers, and would like to 
submit a revised version of our manuscript. In this revised manuscript we have attended to all 
the comments and points raised by the reviewers, and these are detailed below. 
 
 
Reviewer #1  
1. From analyzing the ExAC exome variant database, it seems the STYXL1 variant is not so rare in 
the African populations, with 4% being carriers and 3 homozygous individuals in the database. It 
is difficult to reconcile this with the stated hypothesis that this variant is a cause for ID and 
epilepsy. 
R: This new exome database was launched recently, after submission of our manuscript and 
indeed this is a very useful database. However, we believe that one needs to interpret the data 
with caution since the exomes and genotype data present in this database are both from 
healthy and disease-specific populations, including several psychiatric and behavioral disorders. 
We have no further data on the 3 homozygous individuals, to which study they belonged and 
how well they were phenotyped. Especially, given the mild and psychiatric phenotypes in our 
individuals, this might be overlooked.  
Moreover, the goal of the “Exome Report” section, if we understand well, is the dissemination 
of possible genotype-phenotype correlations without the necessity to reach strong functional 
evidences, or to wait a second case for data replication. The variants are predicted to be 
pathogenic by all prediction programs used, they segregate in the family and match the 
homozygousity data. 
 
2. It is not clear to me why the authors decided to look at mRNA expression levels for a 
missense-encoding SNP. Also, the stated hypotheses in the discussion as to why the mRNA 
levels would be lower are not convincing and in one case not valid. 
R: We agree that the changes in protein confirmation do not affect mRNA expression levels and 
have deleted this in the manuscript’s discussion. Since we received a cell line, we checked mRNA 
levels and found to our surprise a much lower level in the affected versus the controls, even 
after repeating the experiment with different primer sets. Missense mutation usually do not 
trigger non-sense mediated decay, so we needed to think about other potential hypotheses. We 
*Response to Reviewers
have added another hypotheses, regarding splicing, recently described by Xiong HY and co-
workers in Science 2015. 
 
 
Reviewer #2  
1. Both the Figure 1 and 2 (except the pedigree chart) are not informative at all, and it is beyond 
our limit visually, to read the figures. The info in the figures can just be described in the text. 
Please consider to put these figures in supplementary.  
R: We have uploaded the Figures separately. Figure 1 shows the results of the homozygosity 
mapping performed in all members of the family, and shows the linkage interval and the 
position of the STYXL1 gene. 
 
2. Why homozygosity mapping approach was not considered in the affected and unaffected 
children, which is a powerful method to narrow down the regions for recessive causative 
mutations especially in the case of consanguineous. 
R: Homozygosity mapping was performed in all members of the family, as stated in the 
submitted manuscript p7 and Figure 1.  
 
3. Why the mutation in STYXL1 was not tested in other affected and unaffected children 
(although it has been shown indirectly through segregation)? 
R: It was tested in all children, both affected and normal, and segregates with the phenotype, 
this was stated in the submitted manuscript p 7. 
 
4. Please explain why a MAF 3% was used in filtering? Any data to support this cutoff?  
R: To our knowledge, there’s as yet no consensus on the ideal filtering approach in whole-
exome sequencing for recessive disorders. In this family, we were looking for an autosomal 
recessive pathogenic variant leading to non-syndromic ID and epilepsy. Therefore, we could 
allow a certain number of carriers in the normal population. Previous studies mention cut-offs of 
0.5-2% and in order to make sure not to miss any relevant variants, we decided to use the less 
stringent 3%. The access of variants that this relatively high percentage would cause, could 
subsequently be filtered out by other methods, e.g. segregation in the siblings, as is described in 
the results section.  
 
5. Why filtering approach for X-linked variants was applied? Are the affected children all males, 
or x-linked transmission is suspected? 
R: Because the 3 affected children are male, we did want to exclude an X-linked cause (see 
pedigree Figure 1). That is the reason for doing X-inactivation studies in the mother and 
specifically filtering for X-linked variants. 
 
6. Any analysis had been done using tools such as PolyPhen, SIFT etc to predict the functional 
impacts and evolutionary conservation of the variants found in the 2 potential candidate genes? 
R: This analysis was done but we now have explicitly added the outcomes of SIFT, PolyPhen-2 
and MutationTaster2 predictions in the results section. 
 
 
 
 
 
We hope that we have fully addressed all comments of the reviewers to their satisfaction and 
that you will consider this revised manuscript for publication. 
 
 
 
Yours sincerely, 
 
Dr. Hilde Van Esch       
Center for Human Genetics 
Herestraat 49 
B-3000 Leuven 
Belgium        
Tel : +32-16-345903 
Fax : +32-16-346051 
E-mail : Hilde.VanEsch@med.kuleuven.ac.be 
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